Galectin Therapeutics Inc. (NASDAQ:GALT – Get Free Report) Director Kevin D. Freeman purchased 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, October 16th. The stock was acquired at an average cost of $2.70 per share, for a total transaction of $13,500.00. Following the transaction, the director now owns 33,469 shares in the company, valued at $90,366.30. This represents a 0.00 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.
Galectin Therapeutics Stock Performance
NASDAQ:GALT opened at $2.66 on Friday. Galectin Therapeutics Inc. has a 52 week low of $1.55 and a 52 week high of $4.27. The firm has a 50-day moving average price of $2.57 and a two-hundred day moving average price of $2.73. The firm has a market cap of $165.31 million, a price-to-earnings ratio of -3.59 and a beta of 0.61.
Galectin Therapeutics (NASDAQ:GALT – Get Free Report) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.04). As a group, sell-side analysts forecast that Galectin Therapeutics Inc. will post -0.79 earnings per share for the current year.
Institutional Investors Weigh In On Galectin Therapeutics
Wall Street Analysts Forecast Growth
A number of research firms have recently weighed in on GALT. StockNews.com upgraded Galectin Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday. HC Wainwright reaffirmed a “buy” rating and set a $11.00 price objective on shares of Galectin Therapeutics in a report on Friday, August 16th.
View Our Latest Report on Galectin Therapeutics
Galectin Therapeutics Company Profile
Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.
Read More
- Five stocks we like better than Galectin Therapeutics
- About the Markup Calculator
- Taiwan Semiconductor Soars on Earnings With More Room to Run
- Best Aerospace Stocks Investing
- Is Lucid Group Nearing the Bottom? What Investors Should Know
- Investing in Travel Stocks Benefits
- 90% Gain Possible? Analysts Are Bullish on Joby Aviation
Receive News & Ratings for Galectin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.